Search Items: PROTO-ONCOGENE PROTEINS B-RAF - GENETICS , . hits: 44
Ascierto, PA; Mandalà, M; Ferrucci, PF; Guidoboni, M; Rutkowski, P; Ferraresi, V; Arance, A; Guida, M; Maiello, E; Gogas, H; Richtig, E; Fierro, MT; Lebbè, C; Helgadottir, H; Queirolo, P; Spagnolo, F; Tucci, M; Del, Vecchio, M; Gonzales, Cao, M; Minisini, AM; De, Placido, S; Sanmamed, MF; Mallardo, D; Curvietto, M; Melero, I; Palmieri, G; Grimaldi, AM; Giannarelli, D; Dummer, R; Chiarion, Sileni, V
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial.
J Clin Oncol. 2023; 41(2): 212-221.
Doi: 10.1200/JCO.21.02961
Web of Science
PubMed
FullText
FullText_MUG
Seidel, MG; Brcic, L; Hoefler, G; Hutter, C; Minkov, M; Steffen, LS; Zebisch, A; Benesch, M
Concurrence of a kinase-dead BRAF and an oncogenic KRAS gain-of-function mutation in juvenile xanthogranuloma.
Pediatr Blood Cancer. 2023; 70(4):e30060
Doi: 10.1002/pbc.30060
Web of Science
PubMed
FullText
FullText_MUG
Dankner, M; Wang, Y; Fazelzad, R; Johnson, B; Nebhan, CA; Dagogo-Jack, I; Myall, NJ; Richtig, G; Bracht, JWP; Gerlinger, M; Shinozaki, E; Yoshino, T; Kotani, D; Fangusaro, JR; Gautschi, O; Mazieres, J; Sosman, JA; Kopetz, S; Subbiah, V; Davies, MA; Groover, AL; Sullivan, RJ; Flaherty, KT; Johnson, DB; Benedetti, A; Cescon, DW; Spreafico, A; Zogopoulos, G; Rose, AAN
Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors.
JCO Precis Oncol. 2022; 6:e2200107
Doi: 10.1200/PO.22.00107
Web of Science
PubMed
FullText
FullText_MUG
Brcic, I; Dawson, H; Gröchenig, HP; Högenauer, C; Kashofer, K
Serrated Lesions in Inflammatory Bowel Disease: Genotype-Phenotype Correlation.
Int J Surg Pathol. 2021; 29(1):46-53
Doi: 10.1177/1066896920963798
Web of Science
PubMed
FullText
FullText_MUG
Schrom, S; Hebesberger, T; Wallner, SA; Anders, I; Richtig, E; Brandl, W; Hirschmugl, B; Garofalo, M; Bernecker, C; Schlenke, P; Kashofer, K; Wadsack, C; Aigelsreiter, A; Heitzer, E; Riedl, S; Zweytick, D; Kretschmer, N; Richtig, G; Rinner, B
MUG Mel3 Cell Lines Reflect Heterogeneity in Melanoma and Represent a Robust Model for Melanoma in Pregnancy.
Int J Mol Sci. 2021; 22(21):
Doi: 10.3390/ijms222111318
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Deshwar, A; Margonis, GA; Andreatos, N; Barbon, C; Wang, J; Buettner, S; Wagner, D; Sasaki, K; Beer, A; Løes, IM; Pikoulis, E; Damaskos, C; Garmpis, N; Kamphues, K; He, J; Kaczirek, K; Poultsides, G; Lønning, PE; Mischinger, HJ; Aucejo, FN; Kreis, ME; Wolfgang, CL; Weiss, MJ
Double KRAS and BRAF Mutations in Surgically Treated Colorectal Cancer Liver Metastases: An International, Multi-institutional Case Series.
Anticancer Res. 2018; 38(5):2891-2895
Doi: 10.21873/anticanres.12535
(- Case Report)
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Richtig, G; Hoeller, C; Kashofer, K; Aigelsreiter, A; Heinemann, A; Kwong, LN; Pichler, M; Richtig, E
Beyond the BRAFV600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients.
Br J Dermatol. 2017; 177(4):936-944
Doi: 10.1111/bjd.15436
Web of Science
PubMed
FullText
FullText_MUG
Richtig, G; Richtig, E; Kashofer, K; Koch, L; Winter, G; Hoefler, G; Pichler, M; Ehall, B; Grübler, MR; Heinemann, A; Aigelsreiter, A
Testing and clinical implications for non-V600 BRAF mutations in metastatic NRASmt melanoma.
Br J Dermatol. 2017; 177(3):860-861
Doi: 10.1111/bjd.15222
Web of Science
PubMed
FullText
FullText_MUG
Saraggi, D; Salmaso, R; Valentini, E; Munari, G; Vindigni, V; Rugge, M; Fassan, M; Cerroni, L
Pigmented trichoblastoma developed in a sebaceous nevus: HRAS mutation as a common molecular driver.
Pathol Res Pract. 2017; 213(7):860-862
Doi: 10.1016/j.prp.2017.03.012
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
Jahn, SW; Kashofer, K; Halbwedl, I; Winter, G; El-Shabrawi-Caelen, L; Mentzel, T; Hoefler, G; Liegl-Atzwanger, B
Mutational dichotomy in desmoplastic malignant melanoma corroborated by multigene panel analysis.
Mod Pathol. 2015; 28(7):895-903
Doi: 10.1038/modpathol.2015.39
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Kaczirek, K; Ciuleanu, TE; Vrbanec, D; Marton, E; Messinger, D; Liegl-Atzwanger, B; Wrba, F; Knittelfelder, R; Lindner, E; Zielinski, CC; Streubel, B; Brodowicz, T
FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Clin Colorectal Cancer. 2015; 14(2):91-98
Doi: 10.1016/j.clcc.2014.12.003
Web of Science
PubMed
FullText
FullText_MUG
Milewska, M; Romano, D; Herrero, A; Guerriero, ML; Birtwistle, M; Quehenberger, F; Hatzl, S; Kholodenko, BN; Segatto, O; Kolch, W; Zebisch, A
Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation.
PLoS One. 2015; 10(6):e0129859-e0129859
Doi: 10.1371/journal.pone.0129859
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Mössner, R; Zimmer, L; Berking, C; Hoeller, C; Loquai, C; Richtig, E; Kähler, KC; Hassel, JC; Gutzmer, R; Ugurel, S
Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature.
J Eur Acad Dermatol Venereol. 2015; 29(9):1797-1806
Doi: 10.1111/jdv.13039
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
Zalaudek, I; Ciarrocchi, A; Piana, S; Argenziano, G; Torricelli, F; Sancisi, V; Gandolfi, G; Longo, C; Moscarella, E; Banzi, C; Nicoli, D
A novel BRAF mutation in association with primary amelanotic melanoma with oral metastases.
J Eur Acad Dermatol Venereol. 2015; 29(2):387-390
Doi: 10.1111/jdv.12358
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
Goldinger, SM; Zimmer, L; Schulz, C; Ugurel, S; Hoeller, C; Kaehler, KC; Schadendorf, D; Hassel, JC; Becker, J; Hauschild, A; Dummer, R; Dermatology Cooperative Oncology Group (DeCOG)
Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Eur J Cancer. 2014; 50(2):406-410
Doi: 10.1016/j.ejca.2013.09.014
Web of Science
PubMed
FullText
FullText_MUG
Heidenreich, B; Nagore, E; Rachakonda, PS; Garcia-Casado, Z; Requena, C; Traves, V; Becker, J; Soufir, N; Hemminki, K; Kumar, R
Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma.
Nat Commun. 2014; 5(5):3401-3401
Doi: 10.1038/ncomms4401
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Rau, TT; Agaimy, A; Gehoff, A; Geppert, C; Jung, K; Knobloch, K; Langner, C; Lugli, A; Groenbus-Lurkin, I; Nagtegaal, ID; Rüschoff, J; Saegert, X; Sarbia, M; Schneider-Stock, R; Vieth, M; Zwarthoff, EC; Hartmann, A
Defined morphological criteria allow reliable diagnosis of colorectal serrated polyps and predict polyp genetics.
Virchows Arch. 2014; 464(6):663-672
Doi: 10.1007/s00428-014-1569-7
Web of Science
PubMed
FullText
FullText_MUG
Saroufim, M; Novy, M; Taraif, S; Habib, RH; Loya, A; Rauscher, B; Kriegshäuser, G; Oberkanins, C; Khalifeh, I
BRAF mutational epidemiology in dysplastic nevi: does different solar UV radiation exposure matter?
J Eur Acad Dermatol Venereol. 2014; 28(5): 615-625.
Doi: 10.1111/jdv.12148
Web of Science
PubMed
FullText
FullText_MUG
Stadelmeyer, E; Heitzer, E; Resel, M; Cerroni, L; Wolf, P; Dandachi, N
The BRAF V600K mutation is more frequent than the BRAF V600E mutation in melanoma in situ of lentigo maligna type.
J Invest Dermatol. 2014; 134(2):548-550
Doi: 10.1038/jid.2013.338
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Buxhofer-Ausch, V; Ausch, C; Zeillinger, R; Oberkanins, C; Dandachi, N; Reiner-Concin, A; Kriegshäuser, G
Duplex reverse-hybridization assay for the simultaneous detection of KRAS/BRAF mutations in FFPE-extracted genomic DNA from colorectal cancer specimens.
Dis Markers. 2013; 34(3):171-177
Doi: 10.3233/DMA-120960
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Gasch, C; Bauernhofer, T; Pichler, M; Langer-Freitag, S; Reeh, M; Seifert, AM; Mauermann, O; Izbicki, JR; Pantel, K; Riethdorf, S
Heterogeneity of Epidermal Growth Factor Receptor Status and Mutations of KRAS/PIK3CA in Circulating Tumor Cells of Patients with Colorectal Cancer.
Clin Chem. 2013; 59(1):252-260
Doi: 10.1373/clinchem.2012.188557
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Griewank, KG; Westekemper, H; Murali, R; Mach, M; Schilling, B; Wiesner, T; Schimming, T; Livingstone, E; Sucker, A; Grabellus, F; Metz, C; Süsskind, D; Hillen, U; Speicher, MR; Woodman, SE; Steuhl, KP; Schadendorf, D
Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
Clin Cancer Res. 2013; 19(12):3143-3152
Doi: 10.1158/1078-0432.CCR-13-0163
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Hacker, E; Nagore, E; Cerroni, L; Woods, SL; Hayward, NK; Chapman, B; Montgomery, GW; Soyer, HP; Whiteman, DC;
NRAS and BRAF Mutations in Cutaneous Melanoma and the Association with MC1R Genotype: Findings from Spanish and Austrian Populations.
J INVEST DERMATOL. 2013; 133(4): 1027-1033.
Doi: 10.1038/jid.2012.385
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Richtig, E; Schrama, D; Ugurel, S; Fried, I; Niederkorn, A; Massone, C; Becker, JC
BRAF mutation analysis of only one single metastatic lesion can restrict the treatment of melanoma - a case report.
Br J Dermatol. 2013; 168(2):428-430
Doi: 10.1111/j.1365-2133.2012.11121.x
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
Flaherty, KT; Robert, C; Hersey, P; Nathan, P; Garbe, C; Milhem, M; Demidov, LV; Hassel, JC; Rutkowski, P; Mohr, P; Dummer, R; Trefzer, U; Larkin, JMG; Utikal, J; Dreno, B; Nyakas, M; Middleton, MR; Becker, JC; Casey, M; Sherman, LJ; Wu, FS; Ouellet, D; Martin, AM; Patel, K; Schadendorf, D;
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma.
N ENGL J MED. 2012; 367(2): 107-114.
Doi: 10.1056/NEJMoa1203421
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Wiesner, T; Murali, R; Fried, I; Cerroni, L; Busam, K; Kutzner, H; Bastian, BC
A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression.
Am J Surg Pathol. 2012; 36(6):818-830
Doi: 10.1097/PAS.0b013e3182498be5
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Gantner, S; Wiesner, T; Cerroni, L; Lurkin, I; Zwarthoff, EC; Landthaler, M; Hafner, C
Absence of BRAF and HRAS mutations in eruptive Spitz naevi
BRIT J DERMATOL. 2011; 164(4): 873-877.
Doi: 10.1111/j.1365-2133.2011.10210.x
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
Karki, P; Li, X; Schrama, D; Fliegel, L
B-Raf Associates with and Activates the NHE1 Isoform of the Na+/H+ Exchanger.
J Biol Chem. 2011; 286(15): 13096-13105.
Doi: 10.1074/jbc.M110.165134
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Zalaudek, I; Catricalà, C; Moscarella, E; Argenziano, G
What dermoscopy tells us about nevogenesis.
J Dermatol. 2011; 38(1):16-24
Doi: 10.1111/j.1346-8138.2010.01141.x
Web of Science
PubMed
FullText
FullText_MUG
Zalaudek, I; Guelly, C; Pellacani, G; Hofmann-Wellenhof, R; Trajanoski, S; Kittler, H; Scope, A; Marghoob, AA; Longo, C; Leinweber, B; Ferrara, G; Saida, T; Grichnik, JM; Argenziano, G; Becker, JC
The Dermoscopical and Histopathological Patterns of Nevi Correlate with the Frequency of BRAF Mutations.
J Invest Dermatol. 2011; 131(2): 542-545.
Doi: 10.1038/jid.2010.332
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Schrama, D; Kneitz, H; Willmes, C; Adam, C; Houben, R; Becker, JC
Lack of correlation between IGFBP7 expression and BRAF mutational status in melanoma.
J Invest Dermatol. 2010; 130(3):897-898
Doi: 10.1038/jid.2009.304
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Gattenlohner, S; Etschmann, B; Riedmiller, H; Muller-Hermelink, HK
Lack of KRAS and BRAF mutation in renal cell carcinoma.
Eur Urol. 2009; 55(6):1490-1491
Doi: 10.1016/j.eururo.2009.02.024
Web of Science
PubMed
FullText
FullText_MUG
Houben, R; Ortmann, S; Drasche, A; Troppmair, J; Herold, MJ; Becker, JC
Proliferation arrest in B-Raf mutant melanoma cell lines upon MAPK pathway activation.
J Invest Dermatol. 2009; 129(2):406-414
Doi: 10.1038/jid.2008.214
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Pichler, M; Balic, M; Stadelmeyer, E; Ausch, C; Wild, M; Guelly, C; Bauernhofer, T; Samonigg, H; Hoefler, G; Dandachi, N
Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors.
J Mol Diagn. 2009; 11(2):140-147
Doi: 10.2353/jmoldx.2009.080100
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
Vilkin, A; Niv, Y; Nagasaka, T; Morgenstern, S; Levi, Z; Fireman, Z; Fuerst, F; Goel, A; Boland, CR
Microsatellite instability, MLH1 promoter methylation, and BRAF mutation analysis in sporadic colorectal cancers of different ethnic groups in Israel.
Cancer. 2009; 115(4):760-769
Doi: 10.1002/cncr.24019
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Houben, R; Vetter-Kauczok, CS; Ortmann, S; Rapp, UR; Broecker, EB; Becker, JC
Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma.
J Invest Dermatol. 2008; 128(8):2003-2012
Doi: 10.1038/jid.2008.30
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
Schulz, AL; Albrecht, B; Arici, C; van der Burgt, I; Buske, A; Gillessen-Kaesbach, G; Heller, R; Horn, D; Hübner, CA; Korenke, GC; König, R; Kress, W; Krüger, G; Meinecke, P; Mücke, J; Plecko, B; Rossier, E; Schinzel, A; Schulze, A; Seemanova, E; Seidel, H; Spranger, S; Tuysuz, B; Uhrig, S; Wieczorek, D; Kutsche, K; Zenker, M
Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome.
Clin Genet. 2008; 73(1):62-70
Doi: 10.1111/j.1399-0004.2007.00931.x
Web of Science
PubMed
FullText
FullText_MUG
Ugurel, S; Thirumaran, RK; Bloethner, S; Gast, A; Sucker, A; Mueller-Berghaus, J; Rittgen, W; Hemminki, K; Becker, JC; Kumar, R; Schadendorf, D
B-RAF and N-RAS Mutations Are Preserved during Short Time In Vitro Propagation and Differentially Impact Prognosis
PLOS ONE. 2007; 2(2):
Doi: 10.1371/journal.pone.0000236
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
Bloethner, S; Hemminki, K; Thirumaran, RK; Chen, B; Mueller-Berghaus, J; Ugurel, S; Schadendorf, D; Kumar, R
Differences in global gene expression in melanoma cell lines with and without homozygous deletion of the CDKN2A locus genes.
Melanoma Res. 2006; 16(4):297-307
Doi: 10.1097/01.cmr.0000222597.50309.05
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
Fargnoli, MC; Argenziano, G; Zalaudek, I; Peris, K
High- and low-penetrance cutaneous melanoma susceptibility genes.
EXPERT REV ANTICANCER THER. 2006; 6: 657-670.
Doi: 10.1586/14737140.6.5.657
Web of Science
PubMed
FullText
FullText_MUG
Hoek, KS; Schlegel, NC; Brafford, P; Sucker, A; Ugurel, S; Kumar, R; Weber, BL; Nathanson, KL; Phillips, DJ; Herlyn, M; Schadendorf, D; Dummer, R
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.
Pigment Cell Res. 2006; 19(4):290-302
Doi: 10.1111/j.1600-0749.2006.00322.x
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
Houben, R; Michel, B; Vetter-Kauczok, CS; Pfohler, C; Laetsch, B; Wolter, MD; Leonard, JH; Trefzer, U; Ugurel, S; Schrama, D; Becker, JC
Absence of classical MAP kinase pathway signalling in Merkel cell carcinoma.
J Invest Dermatol. 2006; 126(5):1135-1142
Doi: 10.1038/sj.jid.5700170
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
Bloethner, S; Chen, B; Hemminki, K; Müller-Berghaus, J; Ugurel, S; Schadendorf, D; Kumar, R
Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines.
Carcinogenesis. 2005; 26(7):1224-1232
Doi: 10.1093/carcin/bgi066
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
Worda, M; Sreevidya, CS; Ananthaswamy, HN; Cerroni, L; Kerl, H; Wolf, P
T1796A BRAF mutation is absent in Merkel cell carcinoma.
BRIT J DERMATOL. 2005; 153(1): 229-232.
Doi: 10.1111/j.1365-2133.2005.06713.x
Web of Science
PubMed
FullText
FullText_MUG